Stem definition | Drug id | CAS RN |
---|---|---|
systemic antifungal agents, miconazole derivatives | 1800 | 22916-47-8 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
1 | g | O |
0.10 | g | V |
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.89 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 144.18 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 7.14 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.48 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.08 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 19.75 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 8, 1974 | FDA | INSIGHT PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
International normalised ratio increased | 225.47 | 16.36 | 106 | 4790 | 46777 | 46634389 |
Drug interaction | 177.81 | 16.36 | 156 | 4740 | 202938 | 46478228 |
Cholestasis of pregnancy | 57.83 | 16.36 | 15 | 4881 | 1109 | 46680057 |
Haemorrhage subcutaneous | 43.77 | 16.36 | 15 | 4881 | 2891 | 46678275 |
Sepsis neonatal | 39.17 | 16.36 | 9 | 4887 | 400 | 46680766 |
Encephalitis fungal | 38.76 | 16.36 | 6 | 4890 | 27 | 46681139 |
Pericardial effusion | 38.12 | 16.36 | 27 | 4869 | 25516 | 46655650 |
Vulvovaginal burning sensation | 35.29 | 16.36 | 11 | 4885 | 1575 | 46679591 |
Haematuria | 34.66 | 16.36 | 26 | 4870 | 26832 | 46654334 |
Lip swelling | 31.47 | 16.36 | 24 | 4872 | 25371 | 46655795 |
Full blood count abnormal | 31.39 | 16.36 | 10 | 4886 | 1537 | 46679629 |
Premature labour | 21.77 | 16.36 | 14 | 4882 | 11285 | 46669881 |
Drug withdrawal syndrome neonatal | 21.63 | 16.36 | 8 | 4888 | 1920 | 46679246 |
Haematoma | 20.97 | 16.36 | 21 | 4875 | 31851 | 46649315 |
Fungal infection | 20.44 | 16.36 | 20 | 4876 | 29500 | 46651666 |
Jarisch-Herxheimer reaction | 20.18 | 16.36 | 5 | 4891 | 307 | 46680859 |
Rash erythematous | 19.66 | 16.36 | 21 | 4875 | 34329 | 46646837 |
Drug hypersensitivity | 19.52 | 16.36 | 63 | 4833 | 243762 | 46437404 |
Drug monitoring procedure not performed | 18.94 | 16.36 | 5 | 4891 | 396 | 46680770 |
Nail dystrophy | 18.20 | 16.36 | 5 | 4891 | 460 | 46680706 |
Fungal sepsis | 17.58 | 16.36 | 6 | 4890 | 1141 | 46680025 |
Vulvovaginal inflammation | 17.18 | 16.36 | 5 | 4891 | 567 | 46680599 |
Eosinophilia | 17.14 | 16.36 | 15 | 4881 | 19202 | 46661964 |
Vaginal erosion | 16.72 | 16.36 | 3 | 4893 | 37 | 46681129 |
Vulvovaginal pruritus | 16.40 | 16.36 | 7 | 4889 | 2440 | 46678726 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
International normalised ratio increased | 160.94 | 17.53 | 84 | 2978 | 47655 | 29901761 |
Drug interaction | 140.77 | 17.53 | 134 | 2928 | 199434 | 29749982 |
Coagulation time prolonged | 29.55 | 17.53 | 9 | 3053 | 1225 | 29948191 |
Haematuria | 29.18 | 17.53 | 29 | 3033 | 44805 | 29904611 |
Ocular myasthenia | 26.88 | 17.53 | 6 | 3056 | 240 | 29949176 |
Haemorrhage subcutaneous | 20.68 | 17.53 | 8 | 3054 | 2229 | 29947187 |
Mouth haemorrhage | 20.23 | 17.53 | 10 | 3052 | 5007 | 29944409 |
Vitamin E deficiency | 19.19 | 17.53 | 3 | 3059 | 15 | 29949401 |
Arthritis allergic | 18.33 | 17.53 | 3 | 3059 | 21 | 29949395 |
Genital rash | 17.79 | 17.53 | 5 | 3057 | 514 | 29948902 |
Tongue ulceration | 17.76 | 17.53 | 6 | 3056 | 1136 | 29948280 |
Source | Code | Description |
---|---|---|
ATC | A01AB09 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
ATC | A07AC01 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Imidazole derivatives |
ATC | D01AC02 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | G01AF04 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
ATC | J02AB01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Imidazole derivatives |
ATC | S02AA13 | SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives |
ATC | D01AC52 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
FDA CS | M0002083 | Azoles |
MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D065688 | Cytochrome P-450 CYP2C9 Inhibitors |
MeSH PA | D065692 | Cytochrome P-450 CYP3A Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
FDA EPC | N0000175487 | Azole Antifungal |
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:75282 | ergosterol biosynthesis inhibitors |
CHEBI has role | CHEBI:82891 | glucocorticoid receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea pedis | indication | 6020002 | DOID:12403 |
Candidiasis of skin | indication | 49883006 | |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Candidal vulvovaginitis | indication | 72605008 | DOID:2272 |
Tinea corporis | indication | 84849002 | |
Diaper rash | indication | 91487003 | |
Tinea cruris | indication | 399029005 | |
Onychomycosis due to dermatophyte | indication | 402134005 | |
Oropharyngeal Candidiasis | indication | ||
Paronychia | off-label use | 71906005 | DOID:13117 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.49 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.59 | DRUG MATRIX | |||||
Cannabinoid receptor 1 | GPCR | Ki | 4.78 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.51 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
Adenosine receptor A2a | GPCR | Ki | 5.10 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 7 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.38 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.54 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.18 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.95 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.45 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.30 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.78 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.18 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.81 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.18 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.35 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.39 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.87 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.14 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.80 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 5.27 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.82 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.58 | DRUG MATRIX | |||||
Delta-type opioid receptor | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.73 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Epidermal growth factor receptor | Kinase | IC50 | 4.53 | DRUG MATRIX | |||||
Substance-P receptor | GPCR | Ki | 5.43 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.38 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.56 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 6.58 | DRUG MATRIX | |||||
Type-2 angiotensin II receptor | GPCR | Ki | 5.11 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Melanocortin receptor 4 | GPCR | Ki | 4.92 | DRUG MATRIX | |||||
Melanocortin receptor 5 | GPCR | Ki | 4.67 | DRUG MATRIX | |||||
Melanocortin receptor 3 | GPCR | Ki | 4.79 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | WOMBAT-PK | |||||||
Aromatase | Enzyme | IC50 | 6.22 | CHEMBL | |||||
Malate dehydrogenase cytoplasmic | Enzyme | IC50 | 4.60 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 6.70 | CHEMBL | |||||
Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | Ki | 6.61 | CHEMBL | |||||
Alkaline phosphatase, tissue-nonspecific isozyme | Enzyme | EC50 | 4.15 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 5.42 | CHEMBL | |||||
Beta-1 adrenergic receptor | GPCR | Ki | 5.14 | DRUG MATRIX | |||||
Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 5.33 | DRUG MATRIX | |||||
Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 4.71 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.03 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.69 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.71 | DRUG MATRIX | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.17 | CHEMBL | |||||
Aromatase | Enzyme | EC50 | 6.40 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4.40 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | Kd | 6.70 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.75 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.94 | CHEMBL |
ID | Source |
---|---|
4018555 | VUID |
N0000146875 | NUI |
D00416 | KEGG_DRUG |
22832-87-7 | SECONDARY_CAS_RN |
4018554 | VANDF |
4018555 | VANDF |
C0025942 | UMLSCUI |
CHEBI:6923 | CHEBI |
CHEMBL91 | ChEMBL_ID |
CHEMBL1559 | ChEMBL_ID |
D008825 | MESH_DESCRIPTOR_UI |
DB01110 | DRUGBANK_ID |
2449 | IUPHAR_LIGAND_ID |
2728 | INN_ID |
7NNO0D7S5M | UNII |
4189 | PUBCHEM_CID |
42790 | RXNORM |
1135 | MMSL |
36502 | MMSL |
5112 | MMSL |
5113 | MMSL |
7143 | MMSL |
d00155 | MMSL |
002918 | NDDF |
002919 | NDDF |
372738006 | SNOMEDCT_US |
42720001 | SNOMEDCT_US |
60727003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Good Sense Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-0214 | CREAM | 2 g | VAGINULLL | ANDA | 17 sections |
good sense miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-0825 | CREAM | 2 g | VAGINULLL | ANDA | 17 sections |
basic care miconazole 3 | HUMAN OTC DRUG LABEL | 1 | 0113-7070 | CREAM | 40 mg | VAGINULLL | ANDA | 17 sections |
basic care miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-7825 | CREAM | 2 g | VAGINULLL | ANDA | 17 sections |
Selan Antifungal | HUMAN OTC DRUG LABEL | 1 | 0159-2500 | CREAM | 2 g | TOPICAL | OTC monograph final | 12 sections |
Desenex | HUMAN OTC DRUG LABEL | 1 | 0316-0225 | POWDER | 20 mg | TOPICAL | OTC monograph final | 13 sections |
Zeasorb | HUMAN OTC DRUG LABEL | 1 | 0316-0231 | POWDER | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Zeasorb | HUMAN OTC DRUG LABEL | 1 | 0316-0232 | POWDER | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0363-0557 | SPRAY | 2 g | TOPICAL | OTC monograph final | 13 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0363-0730 | CREAM | 20 mg | VAGINULLL | ANDA | 17 sections |
Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0363-1497 | SPRAY | 2 g | TOPICAL | OTC monograph final | 13 sections |
miconazole 3 | HUMAN OTC DRUG LABEL | 1 | 0363-2070 | CREAM | 40 mg | VAGINULLL | ANDA | 17 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0363-3115 | POWDER | 1.42 g | TOPICAL | OTC monograph final | 13 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0363-4208 | SPRAY | 3 g | TOPICAL | OTC monograph final | 13 sections |
VUSION | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0378-8222 | OINTMENT | 2.50 mg | TOPICAL | NDA authorized generic | 26 sections |
VUSION | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0378-9730 | OINTMENT | 2.50 mg | TOPICAL | NDA | 26 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0472-0730 | CREAM | 20 mg | VAGINULLL | ANDA | 17 sections |
Antifungal | HUMAN OTC DRUG LABEL | 1 | 0472-0735 | CREAM | 20 mg | TOPICAL | OTC MONOGRAPH FINULLL | 13 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0472-1736 | SUPPOSITORY | 100 mg | VAGINULLL | ANDA | 17 sections |
Miconazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-1738 | SUPPOSITORY | 200 mg | VAGINULLL | ANDA | 16 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0536-1134 | CREAM | 20 mg | TOPICAL | OTC MONOGRAPH FINULLL | 14 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0713-0197 | SUPPOSITORY | 100 ug | VAGINULLL | ANDA | 11 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0713-0252 | CREAM | 20 mg | VAGINULLL | ANDA | 11 sections |
fungoid tincture | HUMAN OTC DRUG LABEL | 1 | 0884-0293 | TINCTURE | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0904-7734 | CREAM | 20 mg | VAGINULLL | ANDA | 16 sections |
TRIPLEAF | HUMAN OTC DRUG LABEL | 1 | 11086-040 | PASTE | 2 g | TOPICAL | OTC monograph final | 11 sections |
Aloe Vesta Clear Antifungal 56g | HUMAN OTC DRUG LABEL | 1 | 11099-0003 | OINTMENT | 1.12 g | TOPICAL | OTC monograph final | 10 sections |
Aloe Vesta Clear Antifungal 141g | HUMAN OTC DRUG LABEL | 1 | 11099-0006 | OINTMENT | 2.82 g | TOPICAL | OTC monograph final | 10 sections |
vagisil brand vagistat | HUMAN OTC DRUG LABEL | 1 | 11509-0825 | CREAM | 2 g | VAGINULLL | ANDA | 17 sections |
LotriminAntifungal | HUMAN OTC DRUG LABEL | 1 | 11523-0544 | AEROSOL, POWDER | 20 mg | TOPICAL | OTC monograph final | 14 sections |